Department of Medicine, Division of Gastroenterology and Hepatology, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Int J Mol Sci. 2022 Nov 16;23(22):14133. doi: 10.3390/ijms232214133.
Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine protein kinase involved in multiple normal and pathological cell functions, including cell signalling and metabolism. GSK-3β is highly expressed in the onset and progression of multiple cancers with strong involvement in the regulation of proliferation, apoptosis, and chemoresistance. Multiple studies showed pro- and anti-cancer roles of GSK-3β creating confusion about the benefit of targeting GSK-3β for treating cancer. In this mini-review, we focus on the role of GSK-3β in pancreatic cancer. We demonstrate that the proposed anti-cancer roles of GSK-3β are not relevant to pancreatic cancer, and we argue why GSK-3β is, indeed, a very promising therapeutic target in pancreatic cancer.
糖原合酶激酶 3β(GSK-3β)是一种丝氨酸/苏氨酸蛋白激酶,参与多种正常和病理细胞功能,包括细胞信号转导和代谢。GSK-3β在多种癌症的发生和进展中高度表达,强烈参与增殖、凋亡和化疗耐药的调节。多项研究表明 GSK-3β 具有促癌和抗癌作用,这使得针对 GSK-3β 治疗癌症的益处产生了混淆。在这篇迷你综述中,我们重点关注 GSK-3β 在胰腺癌中的作用。我们证明了 GSK-3β 的拟议抗癌作用与胰腺癌无关,并论证了为什么 GSK-3β 确实是胰腺癌非常有前途的治疗靶点。